43
Growth Score
pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
861194
CV Therapeutics, Inc. is a research-based biopharmaceutical company that manufactures drugs for the treatment of cardiovascular diseases
Acquired by 
Gilead Sciences
Gilead Sciences
About the Company
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States.
CV Therapeutics developed Ranexa, a drug to treat chronic angina;
and Lexiscan, an injection used as a stress agent in cardiovascular procedures.
The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
